Hepatitis C: new clues to better vaccines?

Marian E Major

HCV is a major public health problem in the USA and worldwide with the majority of acute infections progressing to chronicity in the absence of therapy. HCV infection is recognised as one of the major causes of liver disease, and is associated with the majority of liver transplantations in most countries. There have been tremendous advances in antiviral drug treatment for HCV over recent years, and current therapies can clear infections in the vast majority of people treated. However, treatment success can be limited by a range of factors, not least of which include the cost of therapy, which makes access to treatment challenging for many both within the USA and elsewhere. For these reasons, safe, effective and affordable prophylactic vaccines against HCV remain the best long-term hope for bringing the global epidemic under control. Such vaccines will also help to circumvent drug resistance, drug–drug interaction in patients with HIV coinfection, susceptibility of treated individuals to reinfection and drug side effects.

There is strong evidence that an effective HCV vaccine to prevent chronic infection is attainable. A form of protective immunity has been demonstrated in studies of both chimpanzees and humans immunity has been demonstrated in studies of both chimpanzees and humans. However, the specific induction of HCV-specific T-cell responses and modification of viral replication kinetics, in many cases, prevention of chronic infection was not achieved even following homologous challenge. Further advances in understanding T-cell immunity have indicated that the magnitude of a T-cell response is not necessarily a marker of function, and more in-depth analyses such as cytotoxicity, proliferation or polyfunctionality are important to assess quality. We also need to consider cross-protective responses if an HCV vaccine is to be functional worldwide. The majority of vaccine candidates have focused on genotype (GT) 1, despite the prevalence of other GTS in the countries that are most in need of a cost-effective form of HCV control.

In this edition of *Gut*, von Delft et al provide a comprehensive and extensive analysis of cross-reactive T-cell responses against GT1 and GT3 antigenic targets. The publication contains a wealth of data on epitopes recognised by both CD4+ and CD8+ T-cells from patients with HCV GT3 infection and indicates limited cross-reactivity in both chronic and resolved disease. This work provides important information on T-cell specificity for HCV GT3, a highly neglected strain and which characteristics will be most important for the development of broadly protective prophylactic T-cell vaccines against multiple HCV GTS.

The data presented in this analysis of T-cells from patients with HCV infection complement previous data published by the same group analysing T-cell responses induced in human volunteers by vaccination using viral vectors. Swadling et al used chimpanzee adenovirus priming followed by modified vaccinia Ankara (MVA) boosting to induce HCV-specific T-cells against the non-structural proteins of a GT1b strain. They performed detailed analyses of the responses induced by the vaccine, part of which included studies on cross-reactivity. Their analyses showed that the T-cells induced by vaccination were able to target GTs 1a, 3a and 4a sequences in addition to GT1b. However, although the breadth of the cross-reactive responses was maintained, the magnitude of the response against the other GTS was reduced compared with those against the 1b-specific peptides by 40%, 70% and 71% against GT1a, 3a and 4a, respectively.

The difference between the findings of these two studies could simply be due to the magnitude of the specific response. Cross-reactivity in the immunised subjects was tested 1 week after the MVA boost, at the peak of the responses. Not surprisingly, Enzyme-Linked ImmunoSpot (ELIspot) responses were lower in patients with GT3 infection (mean spot forming units (SFU) of 250 million cells against GT3 peptides) compared with those in immunised subjects (mean SFU of 2360 million cells against GT1b peptides). Reductions in reactivity of 40%–70% could certainly render some responses undetectable in patients with HCV infection. An alternative explanation could be that natural infection mainly induces limited T-cell cross-reactivity, whereas a viral vector vaccine can induce qualitatively different T-cells or present a different repertoire of epitopes. Interestingly, although cross-protection from secondary HCV infections has been demonstrated, when persistent infections have occurred, these have often been the result of secondary infections with heterologous viruses. It may certainly be possible that viral vectors induce qualitatively different memory T-cell responses due to different routes of administration and different forms of antigen processing and presentation; whether this can result in better cross-protection remains to be determined.

The studies by von Delft et al prompt some interesting questions and serve to demonstrate the complexity of HCV T-cell studies. How should we assess future vaccine candidates for HCV clinical trials, and which characteristics will be most helpful in predicting vaccine efficacy? Certainly, cross-reactive responses should be considered. These can be inferred from analyses of sequence conservation of dominant epitopes or T-cell targets. However, the recognition of variant epitopes still needs to be confirmed through experimental assays to gain a full understanding of the functional qualities of the cross-reactive T-cells, and the potential these have for long-term memory. Should we move away from whole antigen vaccines and consider targeting specific conserved epitopes such that vaccines containsequences covering multiple HCV GTS? This type of design has been shown to be feasible for an HCV global vaccine.

These questions apply equally to antibody
and T-cell-based vaccines, and to vaccines for a number of other pathogens such as HIV, dengue virus and Ebola virus. It may seem premature to be discussing ways to generate better HCV vaccines when we still do not fully understand the best approach for a type-specific vaccine. However, if we do not consider these issues now, we cannot plan the studies needed to address these problems and take HCV vaccine development to the next level.

Disclaimer

My comments are an informal communication and represent my own best judgement. These comments do not bind or obligate the FDA.

Competing interests

None declared.

Provenance and peer review

Commissioned; internally peer reviewed.

To cite


Received 18 May 2015
Accepted 19 May 2015
Published Online First 19 June 2015

REFERENCES

Hepatitis C: new clues to better vaccines?

Marian E Major

Gut 2016 65: 4-5 originally published online June 19, 2015
doi: 10.1136/gutjnl-2015-309829

Updated information and services can be found at: http://gut.bmj.com/content/65/1/4

These include:

References
This article cites 10 articles, 5 of which you can access for free at: http://gut.bmj.com/content/65/1/4#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/